Opinions

Peter Hodson Omnix Biopharmaceuticals OMRI-Q TOP PICK Nov 20, 2006

Using plasma to stop bleeding in the surgical applications. 200% growth. Sells at about 20 X earnings. Management owns a big chunk. Just reported stellar numbers. Will ultimately get taken over.

Peter Hodson

Owned

Unlock Rating

$29.840

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

PAST TOP PICK

(A Top Pick Nov 20/06. Up 30%.) Missed a quarter and there were competitive threats so he got out and missed the upswing.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Peter Hodson Omnix Biopharmaceuticals OMRI-Q TOP PICK Nov 20, 2006

You might be interested:

Omnix Biopharmaceuticals(OMRI-Q)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Brendan Caldwell

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase Insights

Jim Cramer - Mad Money